The drug combinations currently saving lives in ICUs center on a well-established trio: norepinephrine as the frontline vasopressor to maintain blood pressure, vasopressin added when norepinephrine alone falls short, and hydrocortisone to accelerate shock resolution in the sickest patients. Together with rapid antibiotic administration within the first hour, these medications form the backbone of the Surviving Sepsis Campaign guidelines and remain the standard of care in intensive care units worldwide. A newer experimental approach, enibarcimab, a first-in-class monoclonal antibody guided by precision biomarkers, has shown striking early results, reducing 28-day mortality from 24 percent to 8 percent in a targeted subgroup of septic shock patients. Sepsis is not a fringe concern.
An estimated 166 million cases and 21.4 million deaths were recorded globally in 2021, accounting for nearly one-third of all deaths on the planet. In the United States, it ranks as the third leading cause of death in hospitals, and sepsis-associated mortality climbed more than 30 percent between 2019 and 2021, fueled largely by COVID-19 complications. For families already navigating dementia care, where infections like pneumonia and urinary tract infections are common triggers of sepsis in older adults, understanding the treatments that intensivists rely on can be both urgent and empowering. This article covers the standard ICU drug protocols for septic shock, the rise and fall of the vitamin C combination therapy that generated enormous excitement, the precision medicine breakthrough represented by enibarcimab, and what updated 2025 guidelines mean for patients and their families.
Table of Contents
- What Drug Combinations Are Used to Treat Sepsis in ICUs?
- Why the Vitamin C Cocktail for Sepsis Did Not Deliver on Its Promise
- How Enibarcimab Is Changing the Approach to Septic Shock Treatment
- How ICU Teams Decide Which Sepsis Drug Combination to Use
- Why Sepsis Mortality Remains Stubbornly High Despite Treatment Advances
- What the 2025 Updated Sepsis Guidelines Mean for Patient Care
- The Future of Sepsis Treatment and Precision Medicine
- Conclusion
- Frequently Asked Questions
What Drug Combinations Are Used to Treat Sepsis in ICUs?
The Surviving Sepsis Campaign, an international collaboration led by the Society of Critical Care Medicine, lays out a tiered approach to managing septic shock. The first-line vasopressor is norepinephrine, a potent drug that constricts blood vessels to push mean arterial pressure back to at least 65 mmHg, the minimum threshold needed to keep organs perfused. When norepinephrine doses climb beyond 0.25 to 0.50 micrograms per kilogram per minute without stabilizing the patient, vasopressin is added as a second agent rather than simply increasing norepinephrine further. This pairing works through complementary mechanisms, reducing the risk of the cardiac complications that come with pushing a single drug too hard. Hydrocortisone enters the picture for patients whose shock persists despite vasopressor support for four hours or more. Administered intravenously at 200 milligrams per day, it accelerates shock resolution by roughly a day and a half and reduces the total amount of vasopressor required.
The practical impact for a patient in the ICU is real: faster weaning off pressors can mean fewer days on a ventilator and a shorter ICU stay. For elderly patients with dementia, who are especially vulnerable to the cognitive damage that prolonged critical illness inflicts, every day saved matters. The most time-sensitive element, however, is antibiotics. Guidelines mandate that broad-spectrum antibiotics be started within one hour of recognizing septic shock, because mortality increases measurably with each hour of delay. In practice, this means blood cultures are drawn and antibiotics are pushed before the full picture of the infection is even clear. The combination of vasopressors, corticosteroids, and rapid antibiotics is not glamorous or novel, but it is the proven framework that gives patients the best chance of walking out of the ICU.
Why the Vitamin C Cocktail for Sepsis Did Not Deliver on Its Promise
Few treatments in critical care medicine have generated as much initial excitement, and subsequent disappointment, as the HAT protocol: hydrocortisone combined with high-dose intravenous ascorbic acid (vitamin C) and thiamine. The origin story was compelling. A 2017 retrospective study by Dr. Paul Marik showed hospital mortality of just 8.5 percent in the HAT group compared to 40.4 percent in controls, an adjusted odds ratio of 0.13 that seemed almost too good to be true. Hospitals across the country began adopting the protocol, and patients’ families demanded it. It was, in retrospect, too good to be true in the way it was initially presented.
The VICTAS randomized clinical trial, published in JAMA in 2021, found no significant mortality benefit for the combination. A separate 2022 trial published in the new England Journal of Medicine tested intravenous vitamin C alone in sepsis ICU patients and likewise found no mortality benefit. Meta-analyses pooling data from more than seven randomized controlled trials confirmed that while the HAT combination modestly reduced organ dysfunction scores and the duration of vasopressor use, it had no impact on whether patients actually survived. However, the story is not entirely closed. A 2024 review in Frontiers in Medicine suggested that the combination might still hold benefit for the most severely ill patients, those with the highest organ dysfunction scores and deepest shock. This is a pattern that recurs throughout sepsis research: a treatment that fails in a broad population may still work in a specific subset. For families weighing options with an ICU team, the takeaway is that vitamin C therapy is not harmful but should not be relied upon as a lifesaving intervention, and clinicians who present it as a proven cure are overstating the evidence.
How Enibarcimab Is Changing the Approach to Septic Shock Treatment
The most genuinely exciting development in sepsis treatment is enibarcimab, developed by the German biotech company Adrenomed AG. Unlike the broad-stroke approach of standard vasopressors, enibarcimab is a first-in-class non-blocking monoclonal antibody that targets adrenomedullin, a peptide involved in maintaining blood vessel integrity. Rather than blocking adrenomedullin entirely, the antibody stabilizes it in a way that preserves its protective function while preventing the vascular leak that drives organ failure in septic shock. What makes enibarcimab different from past sepsis drug failures is its use of precision medicine. The Phase II AdrenOSS-2 trial, with subgroup results published in the Journal of Critical Care in May 2025, used two biomarkers, bio-ADM and DPP3, to identify which patients would most likely respond.
In that biomarker-selected group, 28-day mortality dropped from 24 percent to 8 percent, a relative reduction of more than 60 percent. That is the kind of result that changes treatment paradigms, provided it holds up in a larger confirmatory trial. The FDA granted Fast Track designation to enibarcimab in April 2024, signaling that regulators see enough promise to expedite its path to approval. A confirmatory study called the BOOST trial is planned using the same biomarker-guided approach. For patients with dementia who develop sepsis, a population in which aggressive ICU interventions must be weighed against quality of life, a targeted treatment that dramatically reduces mortality in the right patients could shift the calculus of when full ICU-level care is worth pursuing.
How ICU Teams Decide Which Sepsis Drug Combination to Use
The decision tree in an ICU is not one-size-fits-all, and understanding the tradeoffs can help families advocate effectively. When septic shock is first identified, the immediate priority is volume resuscitation with intravenous fluids and starting norepinephrine. If the patient stabilizes, that may be sufficient alongside antibiotics. But if blood pressure remains dangerously low despite adequate fluid and norepinephrine, the team faces a choice: escalate norepinephrine further, which increases the risk of dangerous heart rhythms, or add vasopressin as a second agent. Current guidelines favor adding vasopressin rather than pushing norepinephrine beyond 0.25 to 0.50 micrograms per kilogram per minute.
The rationale is that two drugs working through different receptor pathways are safer than one drug at a very high dose. Hydrocortisone then enters consideration if vasopressor support is still needed after four hours. The tradeoff with corticosteroids is real: while hydrocortisone accelerates shock resolution by about a day and a half, it can raise blood sugar, increase the risk of secondary infections, and cause muscle weakness, all concerns that are amplified in elderly patients who may already have diabetes or frailty. For families of dementia patients, these decisions often intersect with goals-of-care conversations. A patient with advanced dementia who develops sepsis from aspiration pneumonia may benefit from antibiotics and moderate vasopressor support but may not benefit from the full escalation ladder. Understanding what each drug does, and what it costs in terms of side effects and prolonged ICU stays, helps families make informed choices rather than deferring entirely to protocol.
Why Sepsis Mortality Remains Stubbornly High Despite Treatment Advances
Despite decades of research and clear guideline-driven protocols, sepsis mortality remains devastatingly high. Across eight major markets in 2024, the overall sepsis mortality rate stood at 26 percent, meaning roughly one in four diagnosed patients died. For septic shock specifically, the numbers are worse: a mortality rate of 49.7 percent, with 1.4 million cases producing 697,600 deaths. These are not statistics from low-resource settings. They reflect outcomes in hospitals with modern ICUs and trained critical care teams. Part of the explanation is that sepsis is not a single disease but a syndrome, the body’s catastrophic overreaction to infection that can involve wildly different organ systems, pathogens, and patient characteristics.
A treatment that works for a 40-year-old with a urinary source of infection may do nothing for an 80-year-old with dementia whose sepsis originated from aspiration pneumonia. This heterogeneity is precisely why broad interventions like the vitamin C cocktail have failed in general populations but might work in carefully selected subgroups. The other sobering reality is timing. Sepsis often begins subtly, especially in elderly patients and those with cognitive impairment who cannot articulate that something feels wrong. By the time confusion deepens or blood pressure drops, organ damage may already be advanced. The one-hour antibiotic window recommended by guidelines assumes rapid recognition, but in nursing homes and even emergency departments, recognition delays remain common. No drug combination can fully compensate for a diagnosis that comes too late.
What the 2025 Updated Sepsis Guidelines Mean for Patient Care
In July 2025, updated S3 guidelines for sepsis prevention, diagnosis, treatment, and follow-up introduced 29 new recommendations and revised 16 existing ones. The most notable shift is a stronger emphasis on individualized treatment rather than rigid protocol adherence. This is a meaningful evolution. Earlier guideline iterations were intentionally rigid because standardization saved lives in an era when many hospitals had no sepsis protocols at all. Now that baseline compliance is better, the guidelines acknowledge that patient-specific factors, including age, comorbidities, and baseline cognitive function, should influence treatment intensity.
Equally significant is the new emphasis on post-discharge follow-up. Surviving sepsis is not the same as recovering from it. Cognitive impairment, muscle weakness, depression, and recurrent infections plague sepsis survivors for months or years. For patients who already have dementia, a sepsis hospitalization can accelerate cognitive decline in ways that never fully reverse. The updated guidelines explicitly call for structured follow-up care, a recognition that the ICU stay is only one chapter in a much longer story.
The Future of Sepsis Treatment and Precision Medicine
The sepsis treatment pipeline is more active than it has been in years, with 11 products currently in late-stage development across major markets. The direction of the field is unmistakably toward precision medicine, using biomarkers to match specific patients with specific therapies rather than applying the same protocol to everyone. Enibarcimab’s biomarker-guided approach, if validated in the BOOST confirmatory trial, could establish a template that reshapes how sepsis clinical trials are designed and how ICU teams make treatment decisions.
For families navigating dementia care, these advances carry particular weight. Older adults with cognitive impairment are among the most vulnerable to sepsis and the least likely to benefit from aggressive interventions that assume a return to baseline function. A future in which biomarkers can identify, within hours, whether a specific patient is likely to respond to a targeted therapy could transform the goals-of-care conversation from a binary choice between full escalation and comfort measures into something far more nuanced and humane.
Conclusion
The drug combinations saving lives in ICUs today are built on a foundation of rapid antibiotics, norepinephrine as the first-line vasopressor, vasopressin for refractory shock, and hydrocortisone to shorten the duration of hemodynamic instability. While the vitamin C and thiamine cocktail generated enormous hope, rigorous trials have shown it does not reduce mortality in the general sepsis population. The most promising development is enibarcimab, a precision medicine approach that uses biomarkers to identify patients most likely to benefit and has shown a reduction in 28-day mortality from 24 percent to 8 percent in those selected patients.
For families caring for someone with dementia, sepsis is a recurring threat that demands both medical knowledge and honest conversations about goals of care. Understanding what these drug combinations can and cannot do, knowing when escalation is likely to help and when it may only prolong suffering, and staying informed about emerging treatments like biomarker-guided therapies are all ways to ensure that critical decisions are made with clarity rather than crisis. The 2025 guideline updates, with their emphasis on individualized treatment and post-discharge follow-up, suggest that the medical community is finally catching up to what families have long understood: surviving sepsis is only the beginning.
Frequently Asked Questions
What is the most important first step when sepsis is suspected in a hospitalized patient?
Broad-spectrum antibiotics must be administered within one hour of recognizing septic shock. Every hour of delay increases mortality. Blood cultures should be drawn simultaneously, but antibiotic administration should not wait for results.
Does vitamin C help treat sepsis?
High-dose intravenous vitamin C, combined with hydrocortisone and thiamine, was initially promising in a 2017 retrospective study. However, multiple randomized controlled trials, including the VICTAS trial in JAMA and a 2022 NEJM study, found no mortality benefit. It may modestly reduce organ dysfunction scores but should not be considered a lifesaving treatment.
What is enibarcimab and how does it work differently from standard sepsis drugs?
Enibarcimab is a first-in-class monoclonal antibody that targets adrenomedullin, a peptide that helps maintain blood vessel integrity. Unlike vasopressors that broadly constrict blood vessels, enibarcimab stabilizes adrenomedullin to prevent vascular leak. It uses biomarkers to identify which patients will benefit most, and Phase II results showed a reduction in 28-day mortality from 24 percent to 8 percent in the biomarker-selected group.
Are elderly patients with dementia treated differently for sepsis in the ICU?
The treatment protocol itself is the same, but the decision about how aggressively to escalate therapy often differs. The 2025 updated guidelines emphasize individualized treatment, which means baseline cognitive function, quality of life, and goals of care should all factor into decisions about vasopressor escalation and the intensity of ICU interventions.
What is the current mortality rate for septic shock?
Across eight major markets in 2024, septic shock carried a mortality rate of 49.7 percent, meaning nearly half of patients diagnosed with septic shock did not survive. Overall sepsis mortality, including less severe cases, was approximately 26 percent.
